EUVIMEDEUVIMED entdecken
Crossref

Transaortic and transfemoral stent deployment approaches related morphological and clinical outcomes after type II hybrid arch repair for type A aortic dissection

Chuan Tian, Yutong Xiao, Kejian Hu, Chang Shu

Heart and Vessels · 2025

DOI: 10.1007/s00380-024-02482-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Heart and Vessels, 2025. Verfasst von Chuan Tian und 3 weiteren Autor:innen. Beteiligte Einrichtung: Vascular Surgery Center, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy…. Hauptthemen laut MEDLINE: Aortic Dissection, Stents, Aortic Aneurysm, Thoracic, Endovascular Procedures. Die Arbeit nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We aimed to evaluate the false lumen patency and late death outcomes of type II hybrid arch repair for type A aortic dissection (TAAD) using the transaortic (TA) and transfemoral (TF) stent deployment approaches. Patients who underwent type II hybrid arch repair for TAAD between September 2013 and November 2020 were enrolled. False lumen patency (classified as patent false lumen, thrombosed false lumen, or false lumen remodeling) and follow-up death were investigated. Multivariate Cox regression and inverse probability of treatment weighting (IPTW) analyses were used to evaluate the association between the outcomes and stent graft deployment approaches. Of the 129 enrolled patients, 23 (17.8%) and 106 (82.2%) were in the TA and TF groups, respectively. During follow-up (median: 42 months, IQR: 32-82 months), higher risks of patent false lumen (odds ratio [OR]: 4.0, 95% confidence interval [CI]: 1.01-16.6, P = 0.03) and all-cause death (hazards ratio [HR]: 5.8, 95% CI: 1.3-25.8, P = 0.02) were observed in TA group than in TF group. In IPTW analysis, TA group showed consistently higher adjusted risks of patent false lumen (adjusted OR: 4.1, 95% CI: 1.6-10.3, P = 0.003) and all-cause death (adjusted HR: 4.5, 95% CI: 1.1-18.7, P = 0.03) than that of TF group. This study demonstrated the TA and TF deployment approaches related to false lumen patency and survival outcomes after type II hybrid arch repair for TAAD. The TA approach was associated with higher risks of patent false lumen and late death during follow-up. The TF approach should be suggested as the primary choice for stent deployment in type II hybrid arch repair for TAAD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aortic DissectionStentsAortic Aneurysm, ThoracicEndovascular ProceduresBlood Vessel Prosthesis ImplantationAorta, ThoracicBlood Vessel ProsthesisHumansMaleFemaleMiddle AgedRetrospective StudiesTreatment OutcomeFemoral ArteryAgedFollow-Up StudiesTime FactorsVascular PatencyRisk FactorsProsthesis Design

Stichwörter der Autor:innen

Aortic archAortic dissectionHybrid arch repairHypothermic circulatory arrest

Autor:innen und Institutionen

  • Vascular Surgery Center, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 167 North Lishi…

Zitieren

APA

Tian, C., Xiao, Y., Hu, K., & Shu, C. (2025). Transaortic and transfemoral stent deployment approaches related morphological and clinical outcomes after type II hybrid arch repair for type A aortic dissection. Heart and Vessels. https://doi.org/10.1007/s00380-024-02482-7

Vancouver

Tian C, Xiao Y, Hu K, Shu C. Transaortic and transfemoral stent deployment approaches related morphological and clinical outcomes after type II hybrid arch repair for type A aortic dissection. Heart and Vessels. 2025. doi:10.1007/s00380-024-02482-7

BibTeX
@article{Tian2025,
  author = {Tian, Chuan and Xiao, Yutong and Hu, Kejian and Shu, Chang},
  title = {Transaortic and transfemoral stent deployment approaches related morphological and clinical outcomes after type II hybrid arch repair for type A aortic dissection},
  journal = {Heart and Vessels},
  year = {2025},
  doi = {10.1007/s00380-024-02482-7}
}
Kostenlos starten →